Interleukin-10 promoter polymorphism IL10.G and familial early onset psoriasis

Abstract

In conclusion, we failed to confirm the susceptible effect of the G13 allele, but provide the first data for a protective effect of allele 3 (IL10.G9) for familial psoriasis. Our results suggest that the IL10.G polymorphism is not a major locus, but acts as a minor locus.

Combined haplotype analysis of the interleukin-19 and -20 genes: relationship to plaque-type psoriasis

“…[16][17][18] In addition, protective effect of microsatellite marker IL-10.G9 allele 3 for familial psoriasis has been observed using the transmission/ disequilibrium test (TDT) in persons with a positive family history of psoriasis. 19 These results indicate that locus q31-32 on chromosome 1 could be related to psoriasis susceptibility.…”

“…27 Moreover, IL-10.G polymorphism from the IL-10 promoter region has been identified to be protecting against psoriasis. 19 Hensen et al 28 have detected the existence of both susceptible and protective loci in the chromosome 19p13 in patients with plaque-type psoriasis. Similarly, data of the present study in accordance with association analysis in our previous study reveal that in the chromosome 1q32 region different loci have different effects in susceptibility to disease.…”

Psoriasis: genetic associations and immune system changes

“…97 Protective effects conferred by some alleles and haplotypes within this cluster of genes has also been proposed, along with suggestions that some alleles influence severity or clinical course of disease. 98,99 A comprehensive association analysis of alleles and haplotypes within this cluster of genes is warranted in other patient populations.…”

Associations between interleukin-10 polymorphisms and susceptibility to psoriasis: a meta-analysis

“…Meta-analysis was performed on the association between the above-mentioned polymorphisms and psoriasis when at least two relevant studies addressed the issue. Three studies were excluded for the following reasons; a family study [26], or a lack of suitable data [27,28], and thus, eight studies met our inclusion criteria [10][11][12][13][14][15][16][17]. These eight studies involved 1,018 psoriasis patients and 1,186 controls, and five European, two Asian, and one Arab population (Table 1).…”